Ajanta Pharma Ltd
NSE:AJANTPHARM

Watchlist Manager
Ajanta Pharma Ltd Logo
Ajanta Pharma Ltd
NSE:AJANTPHARM
Watchlist
Price: 2 855 INR -1.98%
Market Cap: 356.7B INR

Ajanta Pharma Ltd
Total Current Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Ajanta Pharma Ltd
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Ajanta Pharma Ltd
NSE:AJANTPHARM
Total Current Liabilities
₹11.6B
CAGR 3-Years
18%
CAGR 5-Years
13%
CAGR 10-Years
17%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Total Current Liabilities
₹151B
CAGR 3-Years
24%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Total Current Liabilities
₹63B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
5%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Total Current Liabilities
₹234.2B
CAGR 3-Years
12%
CAGR 5-Years
7%
CAGR 10-Years
5%
Lupin Ltd
NSE:LUPIN
Total Current Liabilities
₹89.6B
CAGR 3-Years
2%
CAGR 5-Years
1%
CAGR 10-Years
7%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Total Current Liabilities
₹44.4B
CAGR 3-Years
4%
CAGR 5-Years
-2%
CAGR 10-Years
3%
No Stocks Found

Ajanta Pharma Ltd
Glance View

Market Cap
356.7B INR
Industry
Pharmaceuticals

In the bustling landscape of the Indian pharmaceutical industry, Ajanta Pharma Ltd. has carved a niche for itself with a blend of strategic innovation and market smartness. Founded in 1973, the company swiftly harnessed the dynamics of a growing market by focusing on specialty therapeutic segments including cardiology, dermatology, ophthalmology, and pain management. With a distinctive approach that merges global aspirations with local market insights, Ajanta Pharma has established itself as a significant player not just in India, but also across over 30 countries. The company's success is driven by its sustained emphasis on research and development, which fuels its capabilities to roll out new, affordable formulations addressing unmet medical needs. Ajanta Pharma’s business model thrives on a two-pronged strategy: focusing on high-growth emerging markets and capitalizing on the constantly evolving healthcare demands in regulated markets like the United States. The company's adeptness at manufacturing efficiency and its vertically integrated operations enable it to maintain competitive cost structures, delivering value through robust margins. The revenue streams are further amplified by its prowess in developing generic drugs for the American market, where it navigates through complex regulatory landscapes to outpace competitors. Underpinned by a strong commitment to quality and patient-centric innovation, Ajanta Pharma’s operations exemplify a balanced growth trajectory, reinforcing its status as a dynamic and responsive healthcare entity.

AJANTPHARM Intrinsic Value
2 161.29 INR
Overvaluation 24%
Intrinsic Value
Price

See Also

What is Ajanta Pharma Ltd's Total Current Liabilities?
Total Current Liabilities
11.6B INR

Based on the financial report for Sep 30, 2025, Ajanta Pharma Ltd's Total Current Liabilities amounts to 11.6B INR.

What is Ajanta Pharma Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
17%

Over the last year, the Total Current Liabilities growth was 28%. The average annual Total Current Liabilities growth rates for Ajanta Pharma Ltd have been 18% over the past three years , 13% over the past five years , and 17% over the past ten years .

Back to Top